Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shenglong Li

Showing results (31-40 of 177) with videos related to

Pageof 18
Sort By:
Cancer Letters|May 20, 2024
The opportunities and challenges of using PD-1/PD-L1 inhibitors for leukemia treatmentMengdan Xu, Shenglong Li
Hepatology International|August 23, 2025
Critical flaws in the predictive model for bacterial infections in older AoCLD patientsYuwei Zhao, Shenglong Li
Anaesthesia|September 15, 2025
The reasons hypoactive delirium is often overlookedShenglong Li, Longfei You
British Journal of Anaesthesia|September 26, 2025
Robotic process automation to identify patients at high risk for perioperative myocardial infarction or injury: advantage or artifact. Comment on Br J Anaesth 2025; 135: 1153-60Shenglong Li, Longfei You
Hepatology (Baltimore, Md.)|October 8, 2025
Letter to the Editor: Dropout dynamics in RT+LT vs LR for pCCA-an overlooked variable?Shenglong Li, Longfei You
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 5, 2025
Flawed FLAURA Comparisons and Nonrandom Biomarker Missingness in U.S. Osimertinib Cohort StudyShenglong Li, Cuicui Wang
Arthritis & Rheumatology (Hoboken, N.J.)|December 9, 2025
Refining the Interpretation of Drug Survival and Safety in VEXAS Syndrome: The Importance of Competing Risks and Exposure TimeYi Pei, Runze Jiang, Shenglong Li
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|April 29, 2017
Poloxamer surface modified trimethyl chitosan nanoparticles for the effective delivery of methotrexate in osteosarcomaShenglong Li, Yuyuan Xiong, Xiaojing Zhang
Molecular Cancer|September 2, 2024
Programmed death receptor (PD-)1/PD-ligand (L)1 in urological cancers : the "all-around warrior" in immunotherapyQiang Liu, Yujing Guan, Shenglong Li
Biochimica Et Biophysica Acta. Reviews on Cancer|December 1, 2023
Targeting tumor and bone microenvironment: Novel therapeutic opportunities for castration-resistant prostate cancer patients with bone metastasisShenglong Li, Yue Kang, Yu Zeng
Pageof 18

Showing results (31-40 of 177) with videos related to

Sort By:
Pageof 18
Cancer Letters|May 20, 2024
The opportunities and challenges of using PD-1/PD-L1 inhibitors for leukemia treatmentMengdan Xu, Shenglong Li
Hepatology International|August 23, 2025
Critical flaws in the predictive model for bacterial infections in older AoCLD patientsYuwei Zhao, Shenglong Li
Anaesthesia|September 15, 2025
The reasons hypoactive delirium is often overlookedShenglong Li, Longfei You
British Journal of Anaesthesia|September 26, 2025
Robotic process automation to identify patients at high risk for perioperative myocardial infarction or injury: advantage or artifact. Comment on Br J Anaesth 2025; 135: 1153-60Shenglong Li, Longfei You
Hepatology (Baltimore, Md.)|October 8, 2025
Letter to the Editor: Dropout dynamics in RT+LT vs LR for pCCA-an overlooked variable?Shenglong Li, Longfei You
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 5, 2025
Flawed FLAURA Comparisons and Nonrandom Biomarker Missingness in U.S. Osimertinib Cohort StudyShenglong Li, Cuicui Wang
Arthritis & Rheumatology (Hoboken, N.J.)|December 9, 2025
Refining the Interpretation of Drug Survival and Safety in VEXAS Syndrome: The Importance of Competing Risks and Exposure TimeYi Pei, Runze Jiang, Shenglong Li
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|April 29, 2017
Poloxamer surface modified trimethyl chitosan nanoparticles for the effective delivery of methotrexate in osteosarcomaShenglong Li, Yuyuan Xiong, Xiaojing Zhang
Molecular Cancer|September 2, 2024
Programmed death receptor (PD-)1/PD-ligand (L)1 in urological cancers : the "all-around warrior" in immunotherapyQiang Liu, Yujing Guan, Shenglong Li
Biochimica Et Biophysica Acta. Reviews on Cancer|December 1, 2023
Targeting tumor and bone microenvironment: Novel therapeutic opportunities for castration-resistant prostate cancer patients with bone metastasisShenglong Li, Yue Kang, Yu Zeng
Pageof 18